VINCERX PHARMA INC (VINC) Stock Price, Forecast & Analysis
USA - NASDAQ:VINC - US92731L3042 - Common Stock
VINC Key Statistics, Chart & Performance
The current stock price of VINC is 0.1 USD. In the past month the price decreased by -83.87%. In the past year, price decreased by -99.32%.
VINC Latest News, Press Relases and Analysis
VINC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About VINC
Company Profile
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Company Info
VINCERX PHARMA INC
260 Sheridan Avenue, Suite 400
Palo Alto CALIFORNIA 94306 US
CEO: Ahmed M. Hamdy
Employees: 42
Phone: 16508006676
VINCERX PHARMA INC / VINC FAQ
What does VINCERX PHARMA INC do?
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
What is the stock price of VINCERX PHARMA INC today?
The current stock price of VINC is 0.1 USD. The price decreased by -24.98% in the last trading session.
What is the dividend status of VINCERX PHARMA INC?
VINC does not pay a dividend.
How is the ChartMill rating for VINCERX PHARMA INC?
VINC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of VINCERX PHARMA INC (VINC)?
VINCERX PHARMA INC (VINC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.2).
What is the employee count for VINC stock?
VINCERX PHARMA INC (VINC) currently has 42 employees.
What is the Short Interest ratio of VINCERX PHARMA INC (VINC) stock?
The outstanding short interest for VINCERX PHARMA INC (VINC) is 1.35% of its float.
VINC Technical Analysis
VINC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VINC. While VINC seems to be doing ok healthwise, there are quite some concerns on its profitability.
VINC Financial Highlights
Over the last trailing twelve months VINC reported a non-GAAP Earnings per Share(EPS) of -20.2. The EPS decreased by -968.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -375.69% | ||
| ROE | -1104.04% | ||
| Debt/Equity | 0 |
VINC Forecast & Estimates
7 analysts have analysed VINC and the average price target is 204 USD. This implies a price increase of 203900% is expected in the next year compared to the current price of 0.1.